I'm LongbridgeAI, I can summarize articles.Royalty Pharma reported Q2 2026 results with revenue rising 16.5% to $674.14M, driven by cystic fibrosis and new royalty acquisitions. However, net income fell 44.4% to $17.88M, and diluted EPS declined to $0.04 due to share-based compensation from internalization. The company deployed $876.7M in H1 2026 for investments.
Royalty Pharma plc reported results for the 2026 quarter, with revenue rising to $674.14M from $578.67M a year earlier while net income fell to $17.88M and diluted EPS declined to $0.04— per the company's 10-Q filing.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $674.14M | $578.67M | 16.5% |
| Net income² | $17.88M | $32.18M | (44.4%) |
| Diluted EPS³ | $0.04 | $0.07 | (42.9%) |
¹ Reported as “Total income and other revenues”. ² Reported as “Net income attributable to Royalty Pharma plc”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Revenue growth was driven by the cystic fibrosis franchise, Tremfya and newly acquired Imdelltra royalties; overall income from financial royalty assets rose roughly mid-teens year over year.
- Channel and mix shifts within the cystic fibrosis portfolio moved more sales toward Alyftrek, which lowered the blended royalty rate despite stable receipts.
- Brand momentum from launches and approvals — including Imdelltra, Voranigo, Trodelvy, Evrysdi and Tremfya — contributed to royalty increases.
- Operationally, Royalty Pharma completed internalization in May 2025, transitioned to an employee compensation model and recognized substantial share-based compensation expense.
- Investment activity included $876.7M deployed in H1 2026 to acquire royalties and support R&D deals such as arrangements with Teva, J&J co-funding and Neurimmune cliramitug.
Original SEC Filing: Royalty Pharma plc [ RPRX ] - 10-Q - Aug. 05, 2026